Abstract:
An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Abstract:
This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies.
Abstract:
The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.
Abstract:
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
Abstract:
Binding agents, such as antibodies, are described which selectively bind to the cluster-w4 polypeptide of human small cell lung carcinoma cells at a site located at and around valine-57 of the cluster-w4 polypeptide. The binding agents, either alone or linked to a reporter or effector molecule are of use in the diagnosis or treatment of human small cell lung carcinoma. Also described are peptides (A).sub.m -(T).sub.n -(T).sub.o -(K).sub.p -V-(A).sub.q -(G).sub.r -(G).sub.s -(A).sub.t -(L).sub.u having at least one of the core structures K-V-A, T-K-V, or V-A-G for use in the identification and/or preparation of binding agents according to the invention, as diagnostic reagents, or as immunostimulants.
Abstract:
The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract:
The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from anti-body-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein.
Abstract:
The invention relates to a method of obtaining an antibody with a desired function, the method comprising: a) bringing a population of B cells into contact with a capturing agent; b) separating the captured B cells from the uncaptured B cells; c) culturing a plurality of captured B cells wherein said B cells have not been sorted into single B cells immediately prior to culturing; d) screening a plurality of the cultured cells to identify cells capable of producing an antibody with the desired function; and e) obtaining the desired antibody therefrom.
Abstract:
The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.
Abstract:
The invention relates to nucleic acids encoding a synthetic transmembrane region as well as to membrane associated proteins containing these synthetic transmembrane regions. The design of the synthetic transmembrane region allows various properties of a protein, such as its level of expression, and relative response to ligand binding to be tailored as required for a specific purpose.